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Myocardial Perfusion Imaging (MPI) with Single
Photon Emission Computed Tomography (SPECT)
continues to be one of the most commonly performed
non-invasive functional imaging modality for patients
with stable suspected cardiac chest pain1. Worldwide 20
million SPECT studies performed and, in the US alone
approximately 6.5 million studies are done. While MPI
SPECT has high diagnostic accuracy and excellent
prognostic value, recent trends regarding the ‘yield’ of
SPECT in terms of identifying patients with significant
coronary artery disease (CAD) requiring appropriate
medical or revascularisation strategy has been low2-4.
An important contributor to this could be increasing
selection of low pre test likelihood patients for stress
testing based on existing CAD risk estimators.5,6 Other
reasons for the low ‘‘ yield’’ include referral bias, testing asymptomatic patients and use of medical therapy
for slowing down atherosclerosis progression leading to
lower frequency of abnormal scans. In a large single
study of SPECT studies from 1991 to 2009 a marked
decline in overall abnormal SPECT studies was noted
(from 40.9% in 1991 to 8.7% in 2009) along with
marked decline in ischemic SPECT (from 29.6% in
1991 to 5% in 2009).7 These trends have brought to
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attention that the nuclear cardiology world needs to
rethink strategies of how best to utilize SPECT in the
right patient and right clinical setting. This is key to
maintain the value of SPECT as being the ‘‘ gate keeper’’ for further invasive testing when indicated.
The existing pre-test probability (PTP) estimates are
easy to use as information is readily available to the
referrer: age, sex and angina characteristics (DiamondForrester). The downside of PTP is they were formulated back in 1970s using coronary angiography and are
not representative of the chest pain population seen in
daily practice currently. Hence, they consistently tend to
overestimate likelihood of CAD. To address this problem, new modified Diamond and Forrester estimation
and new societal guidelines have been published.8-10
However even with the modifications, the overestimation issue still persists as evident in studies evaluating
the newer models.4,11 In a dramatic change of approach
to evaluation of chest pain the United Kingdom National
Institute of Clinical Excellence (NICE) issued an update
on it original guideline (2010) in 2016 eliminating PTP
and just using clinical judgement if chest pain is typical
or atypical for CAD.12
Thus, there continues to be a need for more efficient
ways to predict an abnormal SPECT scan given significant strain on resources for healthcare service
providers, scrutiny on medical imaging and emergence
of competing modalities such as coronary computed
tomography.
In this backdrop the REFINE SPECT investigators
present their analysis in current issue of Journal of
Nuclear Cardiology, where they leverage the data from a
large multicentre registry. Their primary aim was to
validate findings from a prior single centre study which
showed a strong inverse relationship between left ventricular ejection fraction and scar tissue to the extent of
ischemia.13 In that large single center study of over
27,000 patients the frequency of SPECT ischemia was
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only 6.6% among patients with an LVEF [ 55% but
38.1% for patients with LVEF \ 45% (P \ 0.001). The
frequency of myocardial ischemia was also fourfold
higher among patients with known CAD vs no known
CAD (28.0% vs 6.5%, P \ 0.001) and approximately
threefold higher among patients with typical angina vs
patients with atypical symptoms. Thus REFINE SPECT
registry was used to see if such findings were reproducible in a large multicenter registry.
The REFINE SPECT international registry comprises a large numbers of SPECT scans done with high
efficiency SPECT cameras and contains a rich repository
of clinical, demographic, stress test and SPECT variables.14 The main goal of this registry was to establish a
large SPECT dataset and use machine learning methods to
integrate quantitative date to ‘‘ pre scan ‘‘ clinical variables. The investigators have previously published their
experience from this registry15 showing that even minimal
defects deciphered with quantitative analysis despite
normal visual reads could carry prognostic significance.
In the present study,16 19,690 patients from five centres with a core lab quantitative analysis of MPI SPECT
obtained using ultrafast solid state detector technology has
confirmed that key and well established patient demographics (increasing age, known CAD and male gender) as
important predictors of ischaemia on SPECT MPI in
addition to scan related findings. Also, the investigators
confirm their single center study finding of an inverse
relationship between LV ejection fraction and resting total
perfusion defect (TPD) to prevalence of ischemia. Surprisingly comparing the different symptoms subgroups
(typical angina, atypical angina, non-cardiac chest pain
and asymptomatic), using multivariate analysis, the
authors reported no difference in predictors of ischaemia.
Additionally, prevalence of ischemia was in the following
order based on symptoms: typical angina, asymptomatic
patients, atypical and non-cardiac chest pain. In clinical
practice one would envisage using predictors of ischemia
to not test particularly the asymptomatic and non-cardiac
chest pain groups; but the findings of this study do not help
delineate this important aspect.
A reassuring aspect of predictability of ischemic
SPECT scans shown in this study is that many currently
used clinical risk markers such as age, male gender, typical angina, pharmacologic stress, known CAD, cardiac
risk factors were all associated with abnormal scans. As
shown in Table 4 of this study the top 5 rank order of
predictors of abnormal SPECT in patients with no known
CAD included male gender, lower LV EF, % myocardial
scar, increasing age and typical angina. While most of this
information is readily available and can be giving
weightage for predicting ischemia before ordering tests,
the study findings of scar extent and LV EF as strong
predictors of ischemia are not typically available in
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patients prior to SPECT to use for predicting ischemia.
One could potentially tap into pre-existing information
like prior SPECT or echocardiographic ejection fraction
and extent of visually reported scar if available as an add
on to above factors but this not always available before
SPECT. Also in daily clinical practice it is more important
to known which patients without known CAD could likely
benefit from SPECT rather than those with established
CAD where SPECT is done for either assessment of
residual ischemia or prognostication.
Although the REFINE SPECT registry helps confirm
the relationship between EF, scar and ischemia, significant limitations exist (appropriately acknowledged by the
authors) in this study apart from those discussed above.
This study population is notable for significant heterogeneity of the patient population and varying local
prevalence of CAD at different centers (supplemental
Table 2 of study) and is limited due to its inherent retrospective design with ‘unadjusted’ patient population in
terms of referral bias and unknown confounding factors.
Also as outlined by authors this study was not designed
to’’ a priori’’ develop a predicting algorithm for identifying ischemia on SPECT. It is sobering to see the large
number of ‘‘asymptomatic or non-anginal’’ chest pain
patients (50-70%) undergoing SPECT studies across the
range of ischemic studies. (supplemental Table 3). No
appropriate use criteria was used for test selection in this
real world registry. Although the exact reasons for testing
asymptomatic patients is not stated in this study, is a time
for reflection for clinicians using SPECT to really take a
close look at how we utilize this technology. Leading
cardiac societal recommendations and randomized trials
clearly outline that testing asymptomatic patients is not
associated with improved outcomes and is discouraged
even if significant ischemia is detected in a small proportion of patients. Hopefully as the registry continues to
evolve and machine learning tools are applied, we can
glean further data to be able to identify predictors of
ischemia on SPECT better for appropriate indications and
in the right patient population.
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